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A B S T R A C T
Purpose
CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/
doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the
treatment of patients age $ 65 with early-stage breast cancer. The treatment allowed dosing
adjustments of methotrexate and capecitabine for pretreatment renal function. The purpose of the
current analysis was to assess the relationship between pretreatment renal function and five end
points: toxicity, dose modification, therapy completion, relapse-free survival, and overall survival.
Methods
Pretreatment renal function was defined as creatinine clearance (CrCl) using the Cockcroft-Gault
equation. Multivariable logistic and proportional hazards regression were used to model separately
for each regimen the relationship between CrCl and the first three binary end points and the last two
time-to-event end points, respectively, after adjusting for variables of prognostic importance.
Results
Six hundred nineteen assessable patients were analyzed. The incidence of stage III (moderate) or
stage IV (severe) renal dysfunction was 72%, 64%, and 75% for treatment with cyclophosphamide/
methotrexate/fluorouracil, AC, and capecitabine, respectively. There was no relationship for any
regimen between pretreatment renal function and the five end points. For AC, as CrCl increased, the
odds of nonhematologic toxicity decreased (P = .008), whereas for capecitabine, as CrCl increased,
the odds of experiencing toxicity of any type also increased (P = .035). Patients with renal insuf-
ficiency who received dose modifications were not at increased risk for complications compared
with those who did not have renal insufficiency and received a full dose.
Conclusion
Excluding from clinical trials patients with renal insufficiency but good performance status on the
basis of concern of excessive hematologic toxicity or poor outcomes may not be justified with
appropriate dosing modifications. Results should be considered in the design of clinical trials for
older patients.
J Clin Oncol 34:699-705. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Renal dysfunction is a common comorbidity in
older cancer patients.1-5 It has significant con-
sequences, including exclusion from clinical
trials, increased toxicity from therapy, and pot-
entially poorer clinical outcomes. Much of the
information regarding the association of renal
insufficiency and treatment tolerance in older
adult patients with cancer has been derived from
retrospective subset analyses of clinical trials in which
older patients were a small fraction of participants.
Cancer and Leukemia Group B study (CALGB/
CTSU) 49907, which was designed exclusively for
older patients, thus provides an opportunity to
evaluate the effect of baseline renal dysfunction
on various clinical outcomes. CALGB 49907 was
a prospective phase III trial for the adjuvant
treatment of women age$ 65 with breast cancer.
Patients were randomly assigned to either standard
combination therapy or single-agent treatment.
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Standard therapy consisted of either CMF (cyclophosphamide/
methotrexate/fluorouracil) or AC (cyclophosphamide/doxorubicin),
chosen at physician discretion. Single-agent treatment was the oral
fluoropyrimidine, capecitabine.6 The purpose of the current study
(A171201, Alliance for Clinical Trials in Oncology) was to determine
the relationship between pretreatment renal function and clinical
outcomes as well as toxicity in patients treated in CALGB 499076.
METHODS
Eligibility
Women age $ 65 who had operable, histologically confirmed ade-
nocarcinoma of the breast, with a performance status of 0 to 2 (according
to National Cancer Institute criteria) and a tumor diameter that was
greater than 1 cm were eligible for the treatment on protocol CALGB
49907; status with respect to estrogen receptor, progesterone receptor, and
human epidermal growth factor receptor type 2 was not specified as an
eligibility criterion. Adequate hematologic, renal (CrCl $ 30 mL/min
using Cockcroft-Gault [C-G] equation), and hepatic function as well as
clear surgical margins for the invasive component of the tumor were
required. Patients with hormone receptor–positive tumors were offered
tamoxifen or an aromatase inhibitor after chemotherapy. Patients had to
have an expected survival of greater than 5 years and no medical condition
that would make treatment with this protocol unreasonably hazardous.
Exclusion criteria included any other active cancer or a previous cancer
with a risk of relapse greater than 30%.
Treatment
Patients were randomly assigned with equal probability to standard
chemotherapy (CMF or AC) or capecitabine. The choice of standard
chemotherapy regimen was made at the discretion of the patient or her
physician. The CMF regimen consisted of cyclophosphamide 100 mg/m2
administered orally from days 1 through 14 and methotrexate 40 mg/m2
and fluorouracil 600 mg/m2 administered intravenously on days 1 and 8.
The cycle was repeated every 28 days for six cycles. The AC regimen
consisted of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2
administered intravenously on day 1. The cycle was repeated every 21 days
for four cycles. Capecitabine 2,000 mg/m2 was administered daily for
14 days followed by a 7-day rest period for six cycles.
As a measure of renal function, pretreatment CrCl was calculated
using the modified C-G equation.7 Eligibility required a calculated CrCl of
greater than 30 mL/min. Initial dose calculations in the protocol took the
following into account: methotrexate doses were adjusted if the initial CrCl
was 30 to 80 mL/min (30-50 mL/min, 20 mg/m2; 51-80 mL/min, 30 mg/
m2; . 80 mL/min, 40 mg/m2); capecitabine doses were adjusted if CrCl
was 30 to 50 mL/min (1,500 mg/m2); and the actual weight of the patient
was adjusted to ideal body weight if the actual weight was greater than
30% of ideal body weight.
The first 56 patients assigned to capecitabine received a dose of
2,000 mg/m2 per day in two divided doses for 14 consecutive days, every
3 weeks, for a total of six cycles, and the dose was increased to 2,500 mg/m2
if they had no toxic effects after the first course. Because the toxicity of this
regimenwas unacceptable, the protocol was amended to eliminate the dose
escalation. Dose modifications for all regimens were based on standard
National Cancer Institute toxicity criteria. All patients provided written
institutional review board–approved informed consent that met state,
federal, and institutional guidelines.
Statistical Analysis
In the current analysis, the primary independent variable of interest
was baseline renal function, which was defined as pretreatment CrCl,
calculated using the modified C-G formula. CrCl was also categorized into
levels of renal dysfunction defined by the National Kidney Foundation.8
The level of renal dysfunction with their corresponding CrCl ranges were
as follows: 1, normal ($ 90mL/min); 2, mild (60-89mL/min); 3, moderate
(30-59 mL/min); and 4, severe (15-29 mL/min). Because of the small
number of 1 and 4 patients, renal dysfunction was split into early (normal
and mild, 1 and 2) and late (moderate and severe, 3 and 4). Renal function
was analyzed both on a continuous scale as CrCl and as a dichotomous
variable as stage of kidney dysfunction (early 1 and 2 versus late 3 and 4).
Because results were similar for both the continuous and categorical forms
but the continuous was more predictive, the results shown are from
modeling the continuous variable. There were five end points, the
occurrence or not of any treatment-related grade $ 3 toxicity9; the
occurrence or not of any dose modification; the completion or not of all
protocol therapy; relapse-free survival (RFS); and overall survival (OS).
The toxicity end point was further categorized by to hematologic, non-
hematologic, and overall (any type) toxicity. RFSwas defined as the interval
from study entry until first disease recurrence regardless of site or death
from any cause, whichever occurred first. Recurrence-free survivors were
Table 1. Patient Demographics and Baseline Disease Features
Variable
Regimen
CMF AC Capecitabine
Patients 135 (100) 182 (100) 302 (100)
Age, years
65-69 36 (27) 73 (40) 108 (36)
70-80 92 (68) 102 (56) 180 (60)
$ 80 7 (5) 7 (4) 14 (5)
Performance score
0 or 1 131 (97) 177 (97) 290 (96)
2 4 (3) 5 (3) 12 (4)
Race
White 117 (87) 153 (84) 258 (85)
Black 16 (12) 25 (14) 28 (9)
Other 2 (1) 4 (3) 16 (6)
Receptor
Both ER/PgR-negative 43 (32) 60 (33) 95 (31)
Either ER/PgR-positive 91 (67) 122 (67) 206 (68)
Missing 1 (1) 0 (0) 1 (, 1)
Tumor size, cm
# 2 68 (50) 85 (47) 120 (40)
. 2 and # 5 57 (42) 88 (48) 165 (55)
. 5 9 (7) 9 (5) 17 (6)
Missing 1 (1) 0 (0) 0 (0)
No. of positive nodes
0 31 (23) 58 (32) 95 (31)
1-3 73 (54) 103 (57) 154 (51)
$ 4 31 (23) 20 (11) 49 (16)
Missing 0 (0) 1 (1) 4 (1)
Calculated CrCl, mL/min
# 40 27 (20) 31 (17) 56 (19)
41-49 35 (26) 45 (25) 88 (29)
50-59 36 (27) 40 (22) 82 (27)
$ 60 37 (27) 66 (36) 76 (25)
Renal function by level
1 (normal) 3 (2) 5 (3) 5 (2)
2 (mild) 34 (25) 61 (34) 71 (24)
3 (moderate) 95 (70) 112 (62) 224 (74)
4 (severe) 3 (2) 4 (2) 2 (1)
5 (renal failure) 0 (0) 0 (0) 0 (0)
Renal function dichotomized by level
Level 1 and 2 62 (46) 76 (42) 144 (48)
Level 3 and 4 73 (54) 106 (58) 158 (52)
NOTE. Data are given as No. (%) unless otherwise noted.
Abbreviations: AC, cyclophosphamide/doxorubicin; CMF, cyclophosphamide/
methotrexate/fluorouracil; CrCl, creatinine clearance; ER, estrogen receptor;
PgR, progesterone receptor.
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censored at the date last known to be alive and free from recurrence. OS
was defined as the interval from study entry until death from any cause.
Surviving patients were censored at the last date known to be alive.
Multiple logistic regression was used to model the relationship between
pretreatment renal function and the first three dichotomous end points.
Adjusted odds ratios (aORs) and their 95% CIs were taken from corre-
sponding logistic models. Multiple proportional hazards regression was
used to model the relationship between pretreatment renal function and
OS and RFS; adjusted hazard ratios (aHRs) and their 95% CIs were taken
from corresponding models. The statistical significance of aORs and aHRs
were obtained from Wald x2 tests from respective multivariable models.
Multivariable models included as covariables the demographics of patient
age and race and the clinical variables used in the primary treatment
analysis6 of number of positive nodes, tumor size, and hormone receptor
status. Although CrCl was analyzed on a linear scale, tables show aORs and
aHRs for 10-unit increments for descriptive purposes. Comparison of two
or more proportions was assessed by x2 test. Because CALGB 49907
reported differences in both efficacy and toxicity by treatment regimens of
AC, CMF, and capecitabine, each end point was assessed separately by
treatment regimen.
All tests were performed under a two-sided a level of .05 and are
presented as statistically significant if their P values were less than .05.
However, as they are unadjusted for multiplicities, the true a level is
indeterminate but larger than .05. Study data were collected by CALGB/
Alliance data coordinators and stored in the CALGB/Alliance database.
Analyses of data available in the database as of February 2015 were per-
formed by CALGB/Alliance statisticians using SAS (SAS/STAT User’s
Guide, Version 9.2; SAS Institute, Cary, NC).
RESULTS
Between September 2001 and December 2006, CALGB 49907
accrued 633 patients, 622 of whom received protocol therapy.
Among treated patients, 619 had pretreatment CrCl data and they
comprise the analyzable sample for this report. In this sample, 204
patients died and 415 were censored (388 patients were alive and in
active follow-up, 21 withdrew consent to be followed, and six were
lost to follow-up). The median follow-up time for censored
patients was 8.7 years, with a maximum of 12.4 years.
Table 1 shows demographics and baseline laboratory results.
Patient age, Zubrod (ECOG) performance score, and tumoral
hormone receptor were well balanced among the three regimens.
More than one half of the patients were between age 70 and 79.
Nearly all had a performance score of 0 or 1. Approximately one third
of the sample had hormone receptor (estrogen receptor/progesterone
receptor)–negative tumors. The incidence of node-negative disease
Table 2. Adjusted Effect of Baseline Creatinine Clearance on Study End Points by Regimen
End Point by Regimen % Who Met End Point* OR/HR (95% CI)† P‡
Was dose modified
CMF 71/70 1.14 (0.85 to 1.52) NS
AC 18/12 1.13 (0.84 to 1.49) NS
Capecitabine 68/61 1.10 (0.91 to 1.34) NS
Completed all treatment
CMF 65/65 0.90 (0.69 to 1.18) NS
AC 94/94 0.96 (0.62 to 1.48) NS
Capecitabine 84/80 1.15 (0.90 to 1.47) NS
Experienced grade $ 3 AE
Hematologic
CMF 49/52 0.92 (0.72 to 1.18) NS
AC 56/53 0.97 (0.78 to 1.20) NS
Capecitabine 3/2 1.37 (0.80 to 2.35) NS
Nonhematologic
CMF 41/40 1.07 (0.83 to 1.38) NS
AC 14/31 0.69 (0.52 to 0.91) .008
Capecitabine 39/31 1.21 (1.00 to 1.47) .052
Either hematologic or nonhematologic
CMF 70/68 1.05 (0.80 to 1.38) NS
AC 59/59 0.93 (0.75 to 1.15) NS
Capecitabine 40/32 1.23 (1.01 to 1.45) .035
RFS§
CMF 27/39 1.06 (0.86 to 1.33) NS
AC 34/36 1.08 (0.90 to 1.28) NS
Capecitabine 34/45 0.93 (0.80 to 1.08) NS
OS§
CMF 22/33 1.10 (0.87 to 1.41) NS
AC 27/33 1.05 (0.87 to 1.27) NS
Capecitabine 29/38 0.92 (0.78 to 1.09) NS
Abbreviations: AC, cyclophosphamide/doxorubicin; AE, adverse event; CMF, cyclophosphamide/methotrexate/fluorouracil; HR, hazard ratio; NS, not significant; OR,
odds ratio; OS, overall survival; RFS, relapse-free survival.
*Stage of renal function at baseline (early stage/late stage).
†OR for the following end points: was dose modified, completed all treatment, and experienced grade $ 3 toxicity; taken from the corresponding logistic regression.
The OR represents a 10-unit increase in baseline creatinine clearance. HR for the following end points: RFS and OS; taken from the corresponding proportional hazards
regression. The HR represents a 10-unit increase in baseline creatinine clearance. ORs and HRs are adjusted for race, age, number of positive nodes, tumor size, and
hormone receptor status.
‡From Wald x2 test of main effect of creatinine clearance from multivariable models.
§Met end point for RFS or OS means the patient experienced an RFS or OS event, respectively.
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was slightly lower for patients receiving CMF (23%) compared
with those receiving AC (32%) or capecitabine (31%). Overall,
patients presented with a baseline CrCl range of between 22 and
112 mL/min. The distribution of pretreatment CrCl was similar
among the three regimens with 25th percentiles, medians, and 75th
percentiles of 41, 51, and 62 for CMF; 43, 53, and 67 for AC; and 42,
50, and 60 for capecitabine, respectively. In each regimen,most patients
had moderate baseline renal dysfunction (CrCl, 30-59 mL/min);
few patients had normal renal function (CrCl, . 90 mL/min) or
severe renal function (CrCl, 15-29 mL/min). Seventy-three percent
of patients receiving CMF and 75% of patients receiving capeci-
tabine had high stage (moderate/severe) renal dysfunction com-
pared with only 64% of patients receiving AC (P = .030). Errors in
creatinine clearance calculations led to nine patients being treated
with CrCl less than 30 mL/min.
Dose Modification
Dose modification refers to modification at any time during
treatment. Overall, the incidence of any dose modification on the
AC regimen was considerably lower than that on either the CMF or
capecitabine regimens. However, within each regimen, the inci-
dence of dose modification was similar for patients with early
versus late stages of renal dysfunction (Table 2). Baseline renal
function was not related to dose modification for any regimen.
Completion of All Protocol Treatment
Table 2 also shows the relationship of renal function with
treatment protocol completion: whether patients completed all
treatment per protocol or terminated treatment early for any
reason. Overall, the CMF regimen had the lowest proportion of
patients who completed treatment, whereas the AC regimen had
the highest proportion. Renal function was not related to treatment
completion.
Toxicity
Of the 619 assessable patients, 614 had adverse event data.
Table 2 summarizes the incidence of any hematologic toxicity, any
nonhematologic toxicity, and any toxicity regardless of the type
that occurred during protocol therapy. Pretreatment renal function
did not influence the occurrence of hematologic toxicity regardless
of regimen. Within treatment regimens, the incidence of hema-
tologic toxicity was similar for early and late renal dysfunction.
Baseline renal function was highly related to the occurrence of
nonhematologic toxicity for the AC regimen and very mildly for
the capecitabine regimen, but not related for the CMF regimen. For
patients treated with AC, every 10-unit increase in CrCl was
associated with a 31% decrease in the odds of experiencing at least
one nonhematologic toxicity (aOR, 0.69; 95% CI, 0.52 to 0.91; P =
.008). For capecitabine-treated patients, each 10-unit increase in
CrCl was associated with a 21% increase in the odds of experi-
encing nonhematologic toxicity (aOR, 1.21; 95% CI, 1.00 to 1.47;
P = .052). This unusual finding occurred because 26% of patients
with higher CrCl (early renal function level 1 and 2) experienced
grade $ 3 rash (hand-foot reaction) compared with 12% of
patients with lower CrCl (late renal function level 3 and 4). The
incidence of other toxicities was similar between early and late
stage renal function. The one toxicity of rash affected the overall
nonhematologic toxicity finding for capecitabine.
The probability of experiencing any toxicity increased at a
steady rate over the six-cycle capecitabine treatment beginning at
the end of cycle one. By the end of treatment, the probability of first
experiencing at least one toxicity was approximately 47%. In
contrast, the probability of first experiencing rash was highest at
the end of cycles two (approximately 5%) and three (approximately
11%), and thereafter generally plateaued.
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Fig 1. Overall survival by renal function stage. (A) Cyclophosphamide/metho-
trexate/fluorouracil; (B) cyclophosphamide/doxorubicin; and (C) capecitabine. HR,
hazard ratio; NS, not significant.
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OS and RFS
After controlling for standard prognostic factors, renal
function was not predictive of either OS or RFS regardless of
regimen. Figures 1 and 2 show the relationship of renal function
and OS and RFS, respectively, by stage of renal function, unad-
justed for prognostic variables.
DISCUSSION
Baseline CrCl did not predict whether a patient would receive dose
modification, complete treatment per protocol, or experience
hematologic toxicity for any regimen. It did, however, predict
nonhematologic toxicity as follows. For AC, increased CrCl was
associated with decreased risk (P = .008); for capecitabine, the
relationship was reversed, with increased CrCl predicting increased
risk (P = .052). The finding among patients receiving capecitabine
was attributed to the incidence of rash (hand-foot reaction) among
early stage 1 and 2 patients being double that of late stage 3 and
4 patients (26% versus 12%, respectively). After adjusting for rel-
evant covariates, baseline renal function was not predictive of OS
and RFS for any regimen.
Patients receiving AC with worse renal function had increased
risk of grade 3 nonhematologic toxicity. It is difficult to determine
whether this increased toxicity resulted from renal insufficiency or
other factors. Dose reduction for AC was not required for renal
insufficiency in this trial as it is usually not recommended for the
range of renal function seen in patients participating in clinical
trials. Doxorubicin and its main active metabolite, doxorubicinol,
are not predominantly eliminated in the urine. Studies on renal
insufficiency show that drug exposure, as measured by area under
the curve, is greater in patients with renal insufficiency than in
patients with normal renal function. The half-lives of these two
compounds are the same in both groups; therefore, doxorubicin
may not need dose adjustment in patients with renal insuffi-
ciency.10-12 For cyclophosphamide, nonrenal mechanisms of
elimination predominate and dose reduction with renal insuffi-
ciency is not required. Dose reductions may be important for
patients with more severe renal impairment (ie, CrCl, 30 mL/min).
Whereas patients with CrCl less than 30 mL/min were not eligible
for the trial, calculations of renal function are imperfect, and there
can be significant intrapatient variability over time.13,14
There seems to be a more complex relationship with cape-
citabine and renal function. The increase in grade $ 3 rash in
patients with renal dysfunction levels 1 and 2 at baseline can be a
reflection of an increased dose in patients who had required a dose
modification at baseline. These conclusions are speculative and
deserve further study.
The increased comorbidity associated with aging often pre-
vents participation in clinical trials because patients with end
organ dysfunction are excluded. Renal dysfunction is a common
comorbidity resulting from the predictable physiologic decline
with aging and is often compounded by other issues, such as
hypertension, vascular disease, and medications; it has been
associated with excess mortality.15 Two studies have observed a
high prevalence of renal insufficiency of 33% glomerular filtration
rate (GFR; , 80 mL/min) and 27% (GFR , 90 mL/min) among
patients with cancer.1,16 A total of 50% to 60% of patients with
cancer in the IRMA-1 study had a GFR less than 90 mL/min,
whereas serum creatinine levels were normal in most patients.4,17
The importance of these findings is that many anticancer drugs are
excreted primarily in the urine as unchanged drug or active
metabolites. Therefore, reduction in renal function can potentially
lead to alterations in pharmacokinetics, elevated blood levels of the
drugs, and increased toxicity. This has led to the development of
safety guidelines in patients with renal insufficiency.2,3
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Fig 2. Relapse-free survival by renal function stage. (A) Cyclophosphamide/
methotrexate/fluorouracil; (B) cyclophosphamide/doxorubicin; and (C) capecita-
bine. HR, hazard ratio; NS, not significant.
www.jco.org © 2016 by American Society of Clinical Oncology 703
Effect of Renal Dysfunction on Outcomes in Breast Cancer
There have been few studies to evaluate the effects of renal
insufficiency on toxicity and treatment outcomes. A Gynecologic
Oncology Group database analysis examined carboplatin dosing.
There was no excess of toxicity among patients with CrCl less than
60 mL/min, and such a restriction would have unnecessarily
excluded 15% of patients from the trial.18 In a study of bladder
cancer, the association between CrCl measured by 12 to 24 urine
collections and calculated CrCl was examined. The ability to
complete at least three cycles was statistically significantly related
with a measured CrCl greater than 60 mL/min (P = .02), but not
with calculated CrCl greater than 60 mL/min. The authors con-
cluded that the current formulas estimating CrCl tend to
underestimate measured CrCl, especially in patients older than 65
years, and that these patients may be inappropriately excluded
from cisplatin-based therapy.19
There are a number of limitations of this data analysis—this
was a retrospective analysis, which has inherent limitations.
However, this evaluation was performed on a prospective trial that
exclusively enrolled older patients and not on a subset analysis of a
larger trial in which older patients were a minority. The primary
variable of interest, renal function, was calculated using the
modified C-G equation at protocol enrollment. There have been
various renal function equations proposed as the preferred method
of calculation.20,21 Each of these methods has their limitations as
does measured CrCl.22 Because the C-G equation is the most
common in practice, it was taken to be the most appropriate. The
development of the toxicities could have been a result of other
comorbidities or an interaction of other comorbidities and renal
insufficiency. Therapy-related toxicity is complex, and factors such
as performance status, functional status, end organ function, bone
marrow reserve, and genetics can also play a significant role.
The results of this analysis suggest that with appropriate dose
modification, patients with varying degrees of renal insufficiency
should be able to tolerate standard therapies when combined with
appropriate supportive care measure. Older patients eligible for
clinical trials are a small subset of the overall older patient pop-
ulation and would be expected to have less toxicity and better
outcomes. However, these results can provide guidance and some
reassurance to clinicians treating patients with renal insufficiency.
Because of the increased incidence of renal dysfunction in older
patients, these findings are particularly important. The current
analysis emphasizes that prior to the administration of chemo-
therapy, an estimate of renal function should be obtained. When a
formula such as C-G is used, the results should be evaluated with the
known shortcomings of this calculation23,24; however, it can still add
valuable information and can assist in appropriate dosemodification.
The general exclusion of patients with renal insufficiency from
studies may not be justified, particularly if the drug of interest does
not have renal excretion as its primary mechanism of elimination.
This has unnecessarily decreased the already low participation of
older patients in studies. Clinical trial design, data reporting, and
treatment guidelines need to emphasize these factors.25-27
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